Related Experiment Video
Updated: Dec 13, 2025
An Improved Protocol to Purify and Directly Mono-Biotinylate Recombinant BDNF in a Tube for Cellular Trafficking Studies in Neurons
Published on: July 11, 2020
Improving therapeutic potential of GDNF family ligands
Pia Runeberg-Roos1,2, Richard D Penn3,4
1Institute of Biotechnology, University of Helsinki, PB 56 (Viikinkaari 5D), FIN-00014, Helsinki, Finland. pia.runeberg@helsinki.fi.
Abstract:
The last decade has been a frustrating time for investigators who had envisioned major advances in the treatment of Parkinson's disease using neurotrophic factors. The first trials of glial cell line-derived neurotrophic factor for treating Parkinson's disease were very promising. Later blinded control trials were disappointing, not reaching the predetermined outcomes for improvement in motor function. Consideration of the problems in the studies as well as the biology of the neurotrophins used can potentially lead to more effective therapies. Parkinson's disease presents a multitude of opportunities for the cell biologist wanting to understand its pathology and to find possible new avenues for treatment.
Insights
Glial cell line-derived neurotrophic factor (GDNF) trials for Parkinson's disease showed initial promise but later failed to improve motor function. Re-evaluating study designs and neurotrophin biology is crucial for developing effective Parkinson's treatments.
Area of Science:
- Neuroscience
- Cell Biology
- Neurology
Background:
- Neurotrophic factors, particularly glial cell line-derived neurotrophic factor (GDNF), were once highly anticipated for Parkinson's disease (PD) treatment.
- Early clinical trials of GDNF for PD demonstrated encouraging results, fueling optimism for its therapeutic potential.
Purpose of the Study:
- To analyze the reasons behind the disappointing outcomes of later, blinded control trials for GDNF in Parkinson's disease.
- To explore how a deeper understanding of neurotrophin biology and study design issues can inform future therapeutic strategies for PD.
Main Methods:
- Review of clinical trial data and outcomes for GDNF in Parkinson's disease.
- Analysis of the biological mechanisms of neurotrophins and their relevance to PD pathology.
Main Results:
- Initial promising results from early GDNF trials were not replicated in later, rigorously controlled studies.
- Predetermined motor function improvement outcomes were not met in subsequent blinded trials, indicating therapeutic limitations or design flaws.
Conclusions:
- The disappointing results highlight challenges in translating neurotrophic factor therapies for Parkinson's disease.
- Further investigation into neurotrophin biology and optimization of clinical trial methodologies are essential for advancing PD treatment.
Related Concept Videos
01:27Transducer Mechanism: Enzyme-Linked Receptors
Major types that are helpful drug targets include:
01:00Enzyme-linked Receptors
Neurotrophin (NT) receptors are a family of RTKs, including trkA, trkB, and trkC (tropomyosin-related kinase) receptors. TrkA is specific for nerve growth factor (NGF), neurotrophin-6, and neurotrophin-7. TrkB binds...
01:15G Protein-coupled Receptors
GPCRs are also called heptahelical, 7TM, or serpentine receptors, and consist of seven (H1-H7) transmembrane alpha-helices that span the bilayer to form a cylindrical core. The transmembrane helices are connected by three extracellular loops and three...